香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY （股份代號：9966） 自願公告 KN026新輔助治療HER2陽性乳腺癌III期臨床研究達到主要終點 本公告乃由康寧傑瑞生物製藥（「本公司」，連同其附屬公司，統稱「本集團」）自願 作出，旨在知會本集團股東（「股東」）及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，與石藥集團有限公司（「石藥集 團」）（股份代號：1093）附屬公司上海津曼特生物科技有限公司（「津曼特生物」） 合作開發的KN026聯合注射用多西他賽（白蛋白結合型）(HB1801)用於人表皮生長 因子受體2（「HER2」）陽性（「HER2陽性」）乳腺癌（「BC」）新輔助治療的III期臨床 研究（研究代號：KN026-004），達到預先設定的總體病理完全緩解率（「tpCR」） 的主要終點，結果具有顯著的統計學和臨床意義。 BC是中國女性發病率最高的惡性腫瘤，其中HER2 ...

Investment Rating - The report maintains a "Buy" rating for the company [1][7] Core Insights - The company has made significant progress in its core pipeline, with multiple clinical data readouts expected this year, particularly for its HER2 ADC product, DB-1303, which has successfully reached the primary endpoint in a Phase III trial for HER2+ breast cancer and has submitted a marketing application [4][5] - The company reported a revenue of 1.852 billion yuan for 2025, a decrease of 4.6% year-on-year, primarily due to delays in milestone revenues from core products [3][9] - The company has a strong cash position with 3.325 billion yuan in cash and bank deposits, and has maintained positive operating cash flow for three consecutive years [3][9] Financial Projections - Revenue projections for the company are as follows: 1.774 billion yuan in 2026, 1.603 billion yuan in 2027, and 2.146 billion yuan in 2028, with a notable growth rate of 34% expected in 2028 [7][9] - The company is projected to have a diluted EPS of -28.79 yuan in 2025, improving to -4.18 yuan by 2028 [9][11] - The estimated reasonable market capitalization is 38.365 billion yuan, corresponding to a target price of 425.63 yuan per share [7]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公司董事會（「董事會」）欣然宣佈，近日，本公司自主研發的HLXTE- HAase02（重組人透明質酸酶注射液）（「HLXTE-HAase02」）的1期臨床試驗 申請(IND)獲國家藥品監督管理局(NMPA)批准。本公司擬於條件具備後於中 國境內（不包括中國港澳台地區）開展相關臨床試驗。 B. 關於HLXTE-HAase02 HLXTE-HAase02是本公司自主研發的新型重組人透明質酸酶(rHuPH20)，擬 用於促進皮下注射或皮下輸注藥物擴散和吸收。HLXTE-HAase02在生理條件 下可局部且可逆地特異性解聚皮下組織透明質酸，增大皮下給藥體積，增強 藥物在皮下組織內的分散度和滲透性，進而增加藥物的生物利用度，提高患 者皮下給藥的依從性。HLXTE-HAase02擬用於皮下給藥產品的開發，幫助這 些藥物實現更有效的皮下遞送。非臨床研究顯示，HLXTE-HAase02展現出與 已上市重組人透明質酸產品 ...

關於癌症疫苗臨床前研究的業務進展更新 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：0775） 整體而言，所發表之研究均呈現一致主題：通過理性設計的癌症疫苗，於多個腫瘤靶點及疫苗構建 體之臨床前模型中，均展現強勁免疫原性及顯著的抗腫瘤活性。在發表中展示之該等數據充分印證 順譜醫藥科技從抗原篩選轉化至功能性免疫反應及腫瘤控制上之優勢。在此基礎上，順譜醫藥科技 正加快推進最具潛力之研發項目的新藥臨床試驗申請（IND）支持性研究，並期望透過策略性合作與 全球協作，加快將選定候選疫苗推進至早期臨床開發階段。 務請注意，該研究目前僅處於臨床前階段，本公司尚未開始就該等疫苗進行臨床試驗，故目前概不能 保證相關成果。因此，本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 長江生命科技集團有限公司 公司秘書 楊逸芝 香港，二零二六年三月三十一日 於本公告日期，本公司執行董事為李澤鉅先生（主席）、甘慶林 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Nanjing Leads Biolabs Co., Ltd. 南 京 維 立志博生物科技股份有限公司 （於 中 華 人 民 共 和 國 成 立 的 股 份 有 限 公 司） （股 份 代 號：9887） 自願公告 研究摘要入選2026年AACR年會展示 本公告由南京 維 立志博生物科技股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，以 告 知 本 公 司 股 東 及 潛 在 投 資 者 有 關 本 公 司 的 最 新 業 務 發 展 情 況。 本 公 司 欣 然 宣 布，兩 項 臨 床 前 管 線 研 究 成 果 將 在2026年美國癌症研究協會 （「AACR」）年會上展示。此年會將於2026年4月17日 至22日在美國加利福尼亞州聖 地亞哥的聖地亞哥會議中心舉行。該兩項研究分別展示了本公司於T cell ...

Core Viewpoint - Cinda Biologics is expected to report strong performance in the fiscal year 2025, achieving a net profit of 834 million yuan for the first time, with total revenue reaching 13 billion yuan, representing a year-on-year growth of 38% [1] Financial Performance - Total revenue for Cinda Biologics is projected to be 13 billion yuan, reflecting a year-on-year increase of 38% [1] - Product sales are anticipated to reach 11.9 billion yuan, marking a year-on-year growth of 45% [1] - The company is set to record its first annual net profit of 834 million yuan [1] Investment Outlook - The strong product line innovation capability and global development potential of Cinda Biologics support its transformation into a global biopharmaceutical company [1] - The investment rating for Cinda Biologics is maintained at "Buy," with the target price slightly increased from 110.62 HKD to 113.86 HKD [1]

Core Viewpoint - Cinda Biologics (01801.HK) is expected to report strong performance in the fiscal year 2025, achieving a net profit of 834 million RMB for the first time [1] Financial Performance - Total revenue reached 13 billion RMB, representing a year-on-year growth of 38% [1] - Product sales amounted to 11.9 billion RMB, reflecting a year-on-year increase of 45% [1] Investment Outlook - The company is recognized for its strong product innovation capabilities and global development potential, accelerating its transformation into a global biopharmaceutical player [1] - The investment rating for Cinda Biologics is maintained at "Buy," with the target price slightly increased from 110.62 HKD to 113.86 HKD [1]

Core Viewpoint - CAR-T cell therapy has revolutionized the treatment of hematological malignancies, but its potential in solid tumors remains largely untapped due to antigen heterogeneity and immunosuppressive microenvironments. Recent research identifies uPAR as a promising target to enhance CAR-T therapy effectiveness in solid tumors and potentially in fibrosis and degenerative diseases [2][4][12]. Group 1: CAR-T Cell Therapy in Solid Tumors - CAR-T cell therapy has shown significant success in treating hematological cancers, particularly with CD19 targeting in refractory leukemia and lymphoma, achieving durable remissions [4]. - The efficacy of CAR-T cells in solid tumors is limited due to antigen expression heterogeneity and the immunosuppressive, fibrotic tumor microenvironment (TME) [4][5]. - Current CAR-T strategies rely on lineage-restricted targets like CD19, FOLR1, or PSMA, which limits their applicability and fails to address aggressive tumor states that drive disease progression and resistance [4][5]. Group 2: uPAR as a Target - uPAR (urokinase-type plasminogen activator receptor) is a glycosylphosphatidylinositol-anchored receptor that regulates extracellular matrix remodeling and cell migration, with low expression in normal tissues but upregulated in malignant tumors and fibrotic environments [5][9]. - High levels of uPAR expression correlate with poor clinical outcomes and are associated with tumor aggressiveness and chronic inflammation [5][9]. - The research team established uPAR as a broadly expressed cancer target, particularly in solid tumors with TP53 and RAS pathway mutations, indicating its role in supporting a cancer-promoting ecosystem [9][12]. Group 3: Research Findings and Implications - The study demonstrated that uPAR-targeted CAR-T cells exhibit strong activity in various cancer models, including lung, pancreatic, and ovarian cancers, leading to tumor regression and eradication of systemic metastases [9][10]. - uPAR-targeted CAR-T cells can eliminate both malignant cells and the pathological stroma that supports tumor growth, thus addressing the challenges of immune evasion and treatment resistance [9][12]. - The findings suggest that uPAR could serve as a target not only for CAR-T therapy but also for antibody-drug conjugates (ADCs), antibody delivery radiotherapy, and CAR-NK cell therapies [12][13].

Core Viewpoint - Rongchang Biopharmaceuticals experienced a significant increase in stock price and trading volume, indicating strong market interest and investor confidence in the company [1][2]. Group 1: Financial Performance - For the year 2025, Rongchang Biopharmaceuticals achieved a revenue of 3.251 billion yuan, representing a year-on-year growth of 89.36% [2]. - The net profit attributable to shareholders for the same period was 710 million yuan, reflecting a substantial increase of 148.33% compared to the previous year [2]. Group 2: Stock and Financing Activity - On March 30, Rongchang Biopharmaceuticals saw a stock price increase of 5.52%, with a trading volume of 1.77 billion yuan [1]. - The company had a net financing purchase of 60.09 million yuan on the same day, with a total financing balance of 768 million yuan, which is 3.57% of its market capitalization [1]. - The financing balance is above the 70th percentile of the past year, indicating a high level of investor engagement [1]. Group 3: Shareholder Composition - As of December 31, 2025, the second-largest shareholder is Hong Kong Central Clearing Limited, holding 9.0675 million shares, an increase of 225,700 shares from the previous period [3]. - New institutional investors include Yongying Medical Innovation Mixed Fund, which holds 4.6739 million shares [3]. - Other notable changes include a decrease in holdings by Wan Jia You Xuan and an increase by Hui Tian Fu Innovation Medical Mixed Fund [3].

Core Viewpoint - The chairman and executive director of China Biologic Products Holdings, Xie Qirun, has increased his stake in the company by purchasing 1.748 million shares at a price of HKD 5.73 per share, totaling approximately HKD 10.016 million, resulting in a new holding of about 7.748 million shares, representing 0.04% of the company [1][2]. Summary by Category - **Share Purchase Details** - Xie Qirun acquired 1.748 million shares of China Biologic Products at HKD 5.73 each [1][2] - The total investment amounted to approximately HKD 10.016 million [1][2] - **Post-Purchase Holdings** - After the purchase, Xie Qirun's total shareholding increased to approximately 7.748 million shares [1][2] - The new shareholding percentage is 0.04% of the total shares [1][2]